AG02122
Fibroblast from Skin, Skin
Description:
MULIBREY NANISM
TRIPARTITE MOTIF-CONTAINING PROTEIN 37; TRIM37
Repository
|
NIA Aging Cell Culture Repository
|
Subcollection |
Heritable Diseases |
Biopsy Source
|
Skin
|
Cell Type
|
Fibroblast
|
Tissue Type
|
Skin
|
Transformant
|
Untransformed
|
Sample Source
|
Fibroblast from Skin, Skin
|
Relation to Proband
|
proband
|
Confirmation
|
Clinical summary/Case history
|
ISCN
|
47,XX+5[4]/46,XX[46]
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
PDL at Freeze |
19 |
Passage Frozen |
12 |
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Chromosome Analysis |
|
Gene |
TRIM37 |
Chromosomal Location |
17q22-q23 |
Allelic Variant 1 |
605073.0001; MULIBREY NANISM |
Identified Mutation |
493-2A>G |
|
Gene |
TRIM37 |
Chromosomal Location |
17q22-q23 |
Allelic Variant 2 |
605073.0001; MULIBREY NANISM |
Identified Mutation |
493-2A>G |
Remarks |
The donor was clinically affected. The biopsy was taken ante-mortem on 1/31/77. The culture was initiated using explants of minced skin tissue. The cell morphology is fibroblast-like. The karyotype is 46,XX; normal diploid female. The donor subject is homozygous for a 5 bp deletion at nucleotides 493-497 of the TRIM37 cDNA. An A>G transition in the genomic sequence altering the consensus dinucleotide sequence of the 3 prime splice site (AG) at position -2 from nucleotide 493 of the cDNA results in aberrant splicing at the next AG site. The cDNA deletion caused a frameshift and predicted a stop codon 10 codons downstream. The legacy karyotype description shown in this Remark may not be representative of the current available product. |
Cumulative PDL at Freeze |
19 |
Passage Frozen |
12 |
Split Ratio |
1:2 |
Temperature |
37 C |
Percent CO2 |
5% |
Percent O2 |
AMBIENT |
Medium |
Eagle's Minimum Essential Medium with Earle's salts and non-essential amino acids with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not inactivated |
Substrate |
Gelatin |
Subcultivation Method |
trypsin-EDTA |
Supplement |
- |
|
|